Short answer
PROTHENA CORP PUBLIC LTD CO (PRTA) filed its Q3 2026 10-Q quarterly report on Nov 5, 2026 for the quarter ended Sep 30, 2026. Quarterly revenue was $620,000 (down 74.3% year over year) with net income of −$17M.
Q3 2026 key financials · XBRL
- Revenue
- $620,000
- −74.3% YoY · −38.6% QoQ
- Net income
- −$17M
- +54.8% YoY · +11.2% QoQ
- Operating margin
- -3035.6%
- EPS (diluted)
- −$0.31
- +54.4% YoY · +8.8% QoQ
Source: XBRL data from the PROTHENA CORP PUBLIC LTD CO (PRTA) Q3 2026 10-Q on SEC EDGAR. USD.
PROTHENA CORP PUBLIC LTD CO Q3 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Q3 revenue $0.6M, down 74% YoY from $2.4M, entirely collaboration revenue
- Operating expenses $19.4M, down 54% YoY from $42.7M, driven by lower R&D and G&A
- Nine-month revenue $52.7M, up $43.1M YoY, including $50.0M Novo Nordisk milestone
- Cash $271.4M vs $307.5M at December 31, 2025, with $8.1M operating cash use and $26.8M share repurchases
- 2026 operating and investing cash use expected at approximately $18M to $23M; cash sufficient for at least twelve months
Risk Factors
- Newly highlighted financial trigger: $50.0 million coramitug milestone earned March 9, 2026, with remaining milestones uncertain
- Liquidity risk: $271.4 million cash and equivalents may not fund continued development beyond the next twelve months
- Regulatory compliance risk: EU GDPR violations could incur fines up to €20 million or 4% of global annual turnover
- Operational risk: Roche, Novo Nordisk, and BMS control ongoing clinical development of prasinezumab, coramitug, and moponetug
- Competitive risk: Biosimilar competition could arise sooner if BPCIA exclusivity protections are shortened or unavailable
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other PROTHENA CORP PUBLIC LTD CO quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.